What we do Aurobindo Pharma is a global pharmaceutical company specializing in manufacturing and marketing APIs, generic formulations, and biosimilars across 150+ countries. |
Founded in 1,986 |
Market share Largest generic pharma supplier in the US by prescription volume; top 10 in several European countries. |
Problem solved Provides affordable, high-quality medicines addressing infectious diseases, chronic conditions, and specialty therapeutic needs globally. |
Top clients or who we serve Serves healthcare providers, governments, and patients worldwide; operates B2B and B2C models in regulated and emerging markets. |
Key management Mr. K. Nithyananda Reddy (Vice Chairman & Managing Director), Mr. M. Madan Mohan Reddy (Whole-time Director). |
Our journey and innovations Started in 1986; expanded globally through acquisitions, JV's, and R&D; pioneered semi-synthetic penicillins and biosimilars. |
Where we operate Operations across USA, Europe, India, China, Russia, Africa, Latin America, and other global markets. |
Top products or what we offer Offers antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergics, injectables, and biosimilars. |
Top brands Bevqolva (biosimilar), Dyrupeg, Zefylti, Auronim (pediatric suspension), and over 800 ANDAs filed. |
Raw materials needed Key raw materials include active pharmaceutical ingredients and intermediates such as 6-APA and penicillin derivatives. |
Raw materials supplier Raw materials procured globally including own manufacturing subsidiaries and partners. |
Recurring vs cyclical contribution Majority revenue is recurring through generic drug sales and long-term government contracts. |
Our industry position Among top 5 global producers of semi-synthetic penicillins; leading generic pharma player in US and Europe. |
Financial highlights FY25 consolidated revenue ₹317,237 Cr with 9.4% growth; Net profit ₹34,836 Cr; EBITDA ₹71,730 Cr, driven by formulations business. |
Geographical revenue split USA 46.7%, Europe 29.5%, India 11.3%, Rest of World 13.9%. |
Order book - |
Whats driving growth Growth from new product launches, US and European market expansions, biosimilar approvals, and capacity increases. |
Our future plans Focus on biosimilars commercialization, specialty generics, capacity expansion, and strategic acquisitions globally. |
Our green promise Committed to renewable energy, waste recycling, water conservation, and antimicrobial resistance initiatives. |
Our people and values Over 15,000 employees globally with focus on ethics, diversity, training, and workplace safety. |
Key challenges ahead Regulatory challenges, pricing pressure, global supply chain disruptions, and patent litigations. |
Interesting facts Largest generic pharmaceutical company by US prescription volume; 861 ANDA filings; advanced biosimilar pipeline. |
Risks and strategy Mitigates risks via diversified markets, strong R&D, compliance controls, and strategic partnerships. |
